BofA Securities Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $65
CG Oncology Is Maintained at Buy by B of A Securities
CG Oncology Analyst Ratings
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
BofA Securities Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $65
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
Buy Rating Affirmed for CG Oncology Amid Strong Clinical Performance and Promising Market Prospects
CG Oncology Price Target Announced at $66.00/Share by RBC Capital
RBC Capital Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $66
RBC Initiates CG Oncology at Outperform, Speculative Risk With $66 Price Target
CG Oncology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $75
Buy Rating Justified for CG Oncology's Cretostimogene Due to Superior Safety Profile and Competitive Efficacy
Goldman Sachs Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $52
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
Buy Rating Affirmed for CG Oncology Amid Competitive Landscape and Strong Clinical Results
CG Oncology Price Target Announced at $65.00/Share by Roth MKM
CG Oncology Initiated at Buy by Roth MKM
CG Oncology Analyst Ratings